PHATHOM PHARMACEUTICALS INC

PHAT stock represents ownership in Phathom Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The ticker trades on the Nasdaq under the symbol PHAT. As a stock, it gives investors a claim on the company's future earnings and assets, but its value depends heavily on clinical trial results, regulatory approvals, and product commercialization. For the latest price and market data, refer to the PHAT quote on this page.

PHAT operates in the biotechnology and pharmaceuticals industry, specifically within the gastrointestinal therapeutic area. The company is engaged in the development of novel treatments for acid-related disorders and other digestive conditions. This sector is characterized by high research and development costs, lengthy regulatory pathways, and the potential for significant revenue from approved drugs. Industry dynamics such as patent expirations, competition, and FDA decisions can materially affect PHAT's business prospects.

Recent performance for PHAT depends on clinical updates, regulatory news, and broader market sentiment. As a small-cap biotech, the stock can experience sharp moves in response to trial data or FDA actions. To see the latest price changes, including daily, weekly, and year-to-date performance, please check the live quote and performance chart on this page. Those figures reflect the most current market data available.

Because PHAT is a clinical-stage biopharmaceutical company, traditional valuation metrics like P/E ratios are often not meaningful, as it may have little or no revenue. Instead, investors may consider cash burn rate, pipeline progress, potential market size for its drug candidates, and analyst estimates for future sales. The market capitalization and price-to-book ratio can also provide context. For current valuation multiples and comparisons, refer to the data on this PHAT page.

To buy PHAT stock, you need a brokerage account that offers access to U.S. stock exchanges. Once your account is funded, you can place a buy order for PHAT shares during regular market hours or in extended sessions if your broker supports it. The minimum investment depends on the share price and whether your broker allows fractional shares. For the current price and trading details, see the quote on this page.

Investing in PHAT carries risks typical of clinical-stage biotech companies, including the possibility that drug candidates fail in trials or do not receive regulatory approval. Commercialization risks, competition, and the need for additional capital are also significant. Additionally, the stock may be volatile and thinly traded at times, which can amplify price swings. For the latest risk-related disclosures, review PHAT's SEC filings and the data on this page.